1. The FDA has approved Pfizer's Prevnar 20 pneumococcal conjugate vaccine for use in infants and children aged six weeks to 17 years.
2. Prevnar 20 is designed to prevent invasive pneumococcal disease (IPD) caused by 20 serotypes of Streptococcus pneumoniae included in the vaccine.
3. The vaccine can also be used for the prevention of otitis media caused by seven of the 20 serotypes in children aged 6 weeks through 5 years.
5. The new vaccine builds on the real-world impact of Pfizer's previous pneumococcal vaccines, Prevnar and Prevnar 13.
7. In 2010, Pfizer extended the vaccine's coverage with Prevnar 13, which offered protection against IPD caused by 13 S. pneumoniae types.
9. Phase II data showed the 20-serotype vaccine to be as safe as the previously approved 13-serotype version, and it elicited immune responses against all 20 serotypes after the third dose.
10. Topline data from a pivotal Phase III study demonstrated that a four-dose series of the 20-valent vaccine led to robust immunity against all serotypes with a favorable safety and tolerability profile.